Table 1.
Definition of main morphological image-based response criteria.
| WHO | RECIST 1.0 and 1.1 | mRECIST | EASL | Choi | |
|---|---|---|---|---|---|
| Complete response | Disappearance of all lesions | Disappearance of all target lesions (up to 2 measurable liver lesions) RECIST 1.1 added disappearance of pathologic lymph nodes |
Disappearance of any intratumoural arterial enhancement in all target lesion(s) (up to 2 measurable liver lesions) | Disappearance of any intratumoural (arterial and portal) enhancement in all target lesion(s) (up to 2 measurable liver lesions) | Disappearance of all lesions |
| Partial response | ≥50% decrease in sum of cross-product of target lesion(s) | ≥30% decrease in sum of maximum diameter of target lesion(s) | ≥30% decrease in sum of maximum diameter of viable target lesion(s) | ≥50% decrease in total tumour load∗ of all measurable lesion(s) | Decrease in longest diameter ≥10% or in attenuation (HU) ≥15%. No new lesions and no obvious progression of immeasurable disease |
| Stable disease | Neither PR nor PD | Neither PR nor PD | Neither PR nor PD | Neither PR nor PD | Neither PR nor PD |
| Progressive disease | >25% increase in sum of cross-product of target lesion(s) | >20% increase in sum of diameters. RECIST 1.1 added: must have at least 5 mm absolute increase in sum |
>20% increase in sum of diameters of viable target lesion(s) | ≥25% increase in size of one or more measurable lesion(s) or the appearance of new lesion | Increase in longest diameter ≥10% without meeting tumour attenuation criteria for partial response or the appearance of new lesion |
CR, complete response; HU, Hounsfield unit; PD, progressive disease; PR, partial response; SD, stable disease. Objective response is defined by CR + PR.
∗
Defined as sum of the cross-product of 2 largest diameters or as the sum of surfaces of viable target lesions.